Acorda Therapeutics Inc. (ACOR)

28.35
NASDAQ : Health Technology
Prev Close 28.35
Day Low/High 0.00 / 0.00
52 Wk Low/High 16.55 / 36.35
Avg Volume 599.70K
Exchange NASDAQ
Shares Outstanding 47.48M
Market Cap 1.34B
EPS -4.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Acorda Second Quarter Update: Webcast/Conference Call Scheduled For August 2, 2018

Acorda Second Quarter Update: Webcast/Conference Call Scheduled For August 2, 2018

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its second quarter 2018 update and financial results on Thursday, August 2 at 8:30 a.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACOR, LMST, ORCL, VALE Downgrades: EXFO, NXRT, ONP Initiations: BLNK Read on to get TheStreet Quant Ratings' detailed report:

Acorda To Present Data For INBRIJA™ (levodopa Inhalation Powder) At 2nd Pan American Parkinson's Disease And Movement Disorders Congress

Acorda To Present Data For INBRIJA™ (levodopa Inhalation Powder) At 2nd Pan American Parkinson's Disease And Movement Disorders Congress

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present four encore INBRIJA posters at the upcoming 2 nd Pan American Parkinson's Disease and Movement Disorders Congress taking place June 22-24, 2018 in Miami, Florida.

Acorda Announces EMA Validation Of The MAA Submission For INBRIJA™ (levodopa Inhalation Powder)

Acorda Announces EMA Validation Of The MAA Submission For INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the European Medicines Agency (EMA) has completed formal validation of Acorda's Marketing Authorization Application (MAA) for INBRIJA.

Acorda Therapeutics Reaches Analyst Target Price

In recent trading, shares of Acorda Therapeutics Inc have crossed above the average analyst 12-month target price of $23.29, changing hands for $23.55/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Acorda Provides Financial And Pipeline Update For First Quarter 2018

Acorda Provides Financial And Pipeline Update For First Quarter 2018

Acorda Therapeutics, Inc. (Nasdaq: ACOR) provided a financial and pipeline update for the quarter ended March 31, 2018.

First Week of ACOR May 18th Options Trading

Investors in Acorda Therapeutics Inc saw new options become available this week, for the May 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new May 18th contracts and identified one put and one call contract of particular interest.

Acorda Files Marketing Authorization Application For INBRIJA™ (levodopa Inhalation Powder)

Acorda Files Marketing Authorization Application For INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for INBRIJA.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

Acorda Rallies Parkinson's Community In First-of-Its-Kind Initiative To Foster Better Conversations About Parkinson's Symptoms

Acorda Rallies Parkinson's Community In First-of-Its-Kind Initiative To Foster Better Conversations About Parkinson's Symptoms

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today unveiled the "Live Well.

Acorda Therapeutics To Present At Oppenheimer Healthcare Conference

Acorda Therapeutics To Present At Oppenheimer Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Andrew Hindman, Acorda's Chief Business Development Officer, will present at the Oppenheimer Healthcare Conference on Tuesday, March 20 at 11:30am.

Acorda To Present At Cowen Health Care Conference

Acorda To Present At Cowen Health Care Conference

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.

Acorda Enters Into Cooperation Agreement With Scopia

Acorda Enters Into Cooperation Agreement With Scopia

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it has entered into a cooperation agreement with Scopia Capital Management LP.

First Week of October 19th Options Trading For Acorda Therapeutics (ACOR)

First Week of October 19th Options Trading For Acorda Therapeutics (ACOR)

Investors in Acorda Therapeutics Inc saw new options become available this week, for the October 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Acorda Announces FDA Acceptance Of New Drug Application For INBRIJA™ (levodopa Inhalation Powder)

Acorda Announces FDA Acceptance Of New Drug Application For INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2017

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2017

Acorda Therapeutics, Inc. (Nasdaq: ACOR) provided a financial and pipeline update for the fourth quarter and full year ended December 31, 2017.

Acorda Therapeutics To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Acorda Therapeutics To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Ron Cohen, M.

Acorda Fourth Quarter/Year End 2017 Update

Acorda Fourth Quarter/Year End 2017 Update

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its fourth quarter 2017 financial results and pipeline updates on Thursday, February 15 at 8:30 a.

Notable Thursday Option Activity: ACOR, VHC, TREE

Notable Thursday Option Activity: ACOR, VHC, TREE

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acorda Therapeutics Inc , where a total volume of 4,420 contracts has been traded thus far today, a contract volume which is representative of approximately 442,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 74.2% of ACOR's average daily trading volume over the past month, of 595,775 shares.

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Acorda Therapeutics, Inc.

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Acorda Therapeutics, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Acorda Therapeutics, Inc.

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Acorda Therapeutics, Inc. To Contact The Firm

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Acorda Therapeutics, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

Notable Monday Option Activity: ACOR, MODN, SCHN

Notable Monday Option Activity: ACOR, MODN, SCHN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acorda Therapeutics Inc , where a total of 3,761 contracts have traded so far, representing approximately 376,100 underlying shares. That amounts to about 68% of ACOR's average daily trading volume over the past month of 552,810 shares.

Acorda Announces 2017 AMPYRA Net Sales And Provides 2018 Financial Guidance At J.P. Morgan Healthcare Conference

Acorda Announces 2017 AMPYRA Net Sales And Provides 2018 Financial Guidance At J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (NASDAQ: ACOR) reported AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2017 of $166 million.

ACORDA THERAPEUTICS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Acorda Therapeutics, Inc. To Contact The Firm

ACORDA THERAPEUTICS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Acorda Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Acorda Therapeutics, Inc.

Kessler Topaz Meltzer & Check, LLP Announces Shareholder Lawsuit Filed Against Acorda Therapeutics, Inc.

Kessler Topaz Meltzer & Check, LLP Announces Shareholder Lawsuit Filed Against Acorda Therapeutics, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Acorda Therapeutics, Inc.

Acorda Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference

Acorda Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Acorda Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Acorda Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline

Pomerantz LLP announces that a class action lawsuit has been filed against Acorda Therapeutics, Inc.

T-Mobile US, Take-Two Interactive, Owens Corning: 'Mad Money' Lightning Round

T-Mobile US, Take-Two Interactive, Owens Corning: 'Mad Money' Lightning Round

Jim Cramer highlights T-Mobile US, Take-Two Interactive, Activision Blizzard, Owens Corning and more.

TheStreet Quant Rating: C- (Hold)